share_log

翰森製藥：截至二零二四年十二月三十一日止年度的年度業績公告

HANSOH PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 21 09:30

Summary by Moomoo AI

翰森製藥2024年度業績表現亮眼，收入同比增長21.3%至人民幣122.61億元，溢利增長33.4%至43.72億元。創新藥與合作產品銷售收入達94.77億元，同比增長38.1%，佔總收入比例上升至77.3%。研發開支約27.02億元，佔收入22.0%。董事會建議派發末期股息每股13.53港仙。公司持續推進創新藥研發與商業化，全年多個產品取得重要進展。阿美樂®獲批三項新適應症，昕越®用於IgG4-RD適應症獲優先審評，HS-20093獲FDA突破性療法認定。與GSK、默沙東等達成多項重要合作，其中向默沙東授權HS-10535獲1.12億美元首付款。展望未來，公司將繼續聚焦創新藥研發與國際化戰略，深化抗腫瘤、中樞神經系統、代謝及自身免疫等重大疾病治療領域佈局。通過差異化產品組合與多渠道商業化策略，鞏固市場地位，為長期增長奠定基礎。在ESG方面，公司維持MSCI ESG評級AA級，並連續位居標普全球CSA中國製藥行業首位。
翰森製藥2024年度業績表現亮眼，收入同比增長21.3%至人民幣122.61億元，溢利增長33.4%至43.72億元。創新藥與合作產品銷售收入達94.77億元，同比增長38.1%，佔總收入比例上升至77.3%。研發開支約27.02億元，佔收入22.0%。董事會建議派發末期股息每股13.53港仙。公司持續推進創新藥研發與商業化，全年多個產品取得重要進展。阿美樂®獲批三項新適應症，昕越®用於IgG4-RD適應症獲優先審評，HS-20093獲FDA突破性療法認定。與GSK、默沙東等達成多項重要合作，其中向默沙東授權HS-10535獲1.12億美元首付款。展望未來，公司將繼續聚焦創新藥研發與國際化戰略，深化抗腫瘤、中樞神經系統、代謝及自身免疫等重大疾病治療領域佈局。通過差異化產品組合與多渠道商業化策略，鞏固市場地位，為長期增長奠定基礎。在ESG方面，公司維持MSCI ESG評級AA級，並連續位居標普全球CSA中國製藥行業首位。
HANSOH PHARMA's performance in 2024 is impressive, with revenue increasing by 21.3% year-on-year to 12.261 billion yuan, and profit rising by 33.4% to 4.372 billion yuan. The sales revenue from Innovative Drugs and collaborative products reached 9.477 billion yuan, a year-on-year growth of 38.1%, accounting for 77.3% of total revenue. Research and development expenses were approximately 2.702 billion yuan, accounting for 22.0% of revenue. The Board of Directors has proposed a final dividend of 13.53 Hong Kong cents per share. The company continues to advance the research and commercialization of Innovative Drugs, achieving significant progress for several products throughout the year. AMI-103 has been approved for three new indications, the use of Xinyue® for the IgG4-RD indication has received priority review, and HS-20093 has been granted...Show More
HANSOH PHARMA's performance in 2024 is impressive, with revenue increasing by 21.3% year-on-year to 12.261 billion yuan, and profit rising by 33.4% to 4.372 billion yuan. The sales revenue from Innovative Drugs and collaborative products reached 9.477 billion yuan, a year-on-year growth of 38.1%, accounting for 77.3% of total revenue. Research and development expenses were approximately 2.702 billion yuan, accounting for 22.0% of revenue. The Board of Directors has proposed a final dividend of 13.53 Hong Kong cents per share. The company continues to advance the research and commercialization of Innovative Drugs, achieving significant progress for several products throughout the year. AMI-103 has been approved for three new indications, the use of Xinyue® for the IgG4-RD indication has received priority review, and HS-20093 has been granted breakthrough therapy designation by the FDA. Several important collaborations have been established with GSK, Merck, and others, including a licensing agreement with Merck for HS-10535, which received a $0.112 billion upfront payment. Looking ahead, the company will continue to focus on the research and development of Innovative Drugs and internationalization strategy, deepening its layout in major disease treatment areas such as oncology, central nervous system, metabolism, and autoimmune diseases. By leveraging a differentiated product portfolio and multi-channel commercialization strategy, the company aims to strengthen its market position and lay the foundation for long-term growth. In terms of ESG, the company maintains an MSCI ESG rating of AA and has consistently ranked first in S&P Global CSA for the China pharmaceutical industry.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 362

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
SANAI HEALTH GP
01889
0.290
TIANDA PHARMA
00455
0.184
AIM VACCINE
06660
4.550
HANSOH PHARMA
03692
21.050
PAK FAH YEOW
00239
2.170
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1511 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK